Skip to main content

Coronavirus (COVID-19) - Latest Information for Patients and Visitors

Read Now
SEARCH TEMPLE HEALTH
Neurosciences Center

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

view all Clinical Trials

Overview

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy

Contact

For more information about this trial or to inquire about eligibility, call 215-707-5440 or email theresa.ropars@tuhs.temple.edu.